ClinicalTrials.gg
RecruitingNCT07540416TRUST-MISMATCHUpdated Nov 9, 2026

Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR Mismatch

A Phase 3 interventional study of TNK-tPA and Aspirin in Acute Ischemic Stroke, sponsored by The First Affiliated Hospital of Zhengzhou University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by The First Affiliated Hospital of Zhengzhou University · Phase 3, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
564
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.

Planned enrollment
26th of 59
564 · median 466
Started
2026
with 10 others
Phase 3
37 of 59
23 open now
Primary completion
2028-02
later than 16 of 31 live
Registered
53rd of 59
by date

Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 26th largest by planned enrollment, is one of 11 that started in 2026, is one of 37 in phase 3, reaches primary completion later than 16 of the 31 other live ones, and was the 53rd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About tenecteplase

Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing tenecteplase in Ischemic Stroke, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in patients with acute ischemic stroke (AIS) guided by DWI-FLAIR mismatch on MRI. The main questions it aims to answer are:

  1. Does tenecteplase improve functional outcomes at 90 days compared with standard treatments in AIS patients administered 4.5-9 hours after stroke onset guided by DWI-FLAIR mismatch?
  2. The safety of tenecteplase thrombolysis for AIS patients in the 4.5-9 hours guided by DWI-FLAIR mismatch.

Researchers will compare tenecteplase to placebo to see if it is effective and safe for these patients.

Participants will be randomly assigned (1:1) immediately after randomization:

  • Tenecteplase group: received tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg).
  • Control group: aspirin (300 mg) plus tenecteplase placebo. From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.
Read the detailed description

Current clinical guidelines recommend intravenous thrombolysis (IVT) for eligible AIS patients within 4.5 hours of symptom onset. However, approximately 67 to 75% of patients present after 4.5 hours after stroke onset or with an unknown time of onset. CT perfusion (CTP) and perfusion-diffusion magnetic resonance imaging (MRI) have demonstrated that potentially viable brain tissue may persist beyond 4.5 hours after stroke onset. Recent trials, such as EXTEND, TRACE III, and the HOPE study, suggest that IVT can improve functional outcomes in AIS patients with salvageable brain tissue identified beyond 4.5 hours and up to 24 hours, using advanced perfusion imaging. Nonetheless, due to the high cost of perfusion software in developing countries, extended-window thrombolysis has not been widely implemented in many stroke centers. Therefore, it is crucial to develop alternative strategies to guide IVT in patients beyond 4.5 hours.

In recent years, the mismatch between a visible acute ischemic lesion on diffusion-weighted imaging (DWI) and the absence of a corresponding hyperintensity on fluid-attenuated inversion recovery (FLAIR) has been recognized as a predictor of symptom onset within 4.5 hours before imaging. The WAKE-UP trial demonstrated that among AIS patients with unknown time of onset (last known well >4.5 hours) and DWI-FLAIR mismatch, IVT administered within 4.5 hours after symptom recognition significantly improved functional outcomes. However, approximately 30% of AIS patients exhibit DWI-FLAIR mismatch between 4.5 and 9 hours after onset. Whether these patients can benefit from thrombolysis remains uncertain.

TRUST-MISMATCH is a multicenter, prospective, randomized, double-blind, placebo-controlled clinical. We want to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in AIS patients guided by DWI-FLAIR mismatch on MRI.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Tenecteplase
  • Thrombolysis
  • diffusion weighted imaging
  • fluid attenuated inversion recovery
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years;
  2. AIS with symptom onset 4.5-9 hours before enrollment, including wake-up stroke and unwitnessed stroke (onset time defined as when symptoms were first noticed);
  3. Imaging criteria:

    1. DWI-FLAIR mismatch: visible lesion on DWI with no marked visible lesion on FLAIR;
    2. DWI infarct core not exceeding one-third of the middle cerebral artery territory, one-half of the anterior cerebral artery territory, or one-half of the posterior cerebral artery territory;
  4. NIHSS score 4-25;
  5. First-ever stroke or previous stroke without significant disability (pre-stroke mRS ≤ 1);
  6. Signed from the patient or legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. Planned endovascular treatment;
  2. Contradictory to MRI examination;
  3. MRI image not qualified for evaluation;
  4. Obvious head injuries or strokes within 3 months;
  5. Subarachnoid or intracranial hemorrhage;
  6. History of intracranial hemorrhage;
  7. Intracranial tumor, arteriovenous malformation or aneurysm;
  8. Intracranial or spinal cord surgery within 3 months;
  9. Active internal hemorrhage;
  10. count of \<100000/mm3;
  11. Aortic arch dissection;
  12. Heparin therapy within 24 hours;
  13. Oral warfarin is being taken and >1.6 or APTT abnormal;
  14. Oral anticoagulation therapy;
  15. Systolic pressure≥185 mmHg or diastolic pressure≥110 mmHg;
  16. Blood glucose \< 50 mg/dl (2.7mmol/L);
  17. Pregnancy;
  18. Neurological deficit after epileptic seizures;
  19. Major surgery within 1 month;
  20. Gastrointestinal or urinary tract hemorrhage within the previous 30 days;
  21. Myocardial infarction within 3 months;
  22. Allergy to study drugs;
  23. Unlikely to adhere to the trial protocol or follow-up;
  24. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;
  25. Participation in other interventional clinical trials within the previous 3 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
564 participants (estimated)

Study arms

  • Experimental
    Tenecteplase group:

    Patients will receive tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg) immediately after randomization.From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

    Drug: TNK-tPA · Drug: Placebo

  • Active comparator
    Control group

    Patients will receive asprin(300mg) plus intravenous TNK(placebo, 0.25mg/kg, a maximum of 25 mg) immediately after randomization. From day 2 to day 90, patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

    Drug: Aspirin · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Modified Rankin Scale (mRS)

    Proportion of subjects of excellent outcome defined as mRS (0-1) at 90 ± 7 days.

    Time frame: 90 ± 7 days

Secondary outcomes

  1. Modified Rankin Scale (mRS)

    Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days.

    Time frame: 90 ± 7 days

  2. Modified Rankin Scale (mRS)

    Ordinal shift analysis of mRS at 90 days

    Time frame: 90 days

  3. National Institutes of Health Stroke Scale (NIHSS)

    Proportion of subjects with an improvement in NIHSS score of ≥2 points from baseline.

    Time frame: 72 hours and 7 ± 1 days (or at discharge)

  4. National Institutes of Health Stroke Scale (NIHSS)

    Proportion of subjects achieving an NIHSS score of ≤1.

    Time frame: 72 hours and 7 ± 1 days (or at discharge)

  5. Barthel (BI)

    Barthel Index score at 90 ± 7 days.

    Time frame: 90 ± 7 days

  6. EuroQol 5-Dimension (EQ-5D)

    Quality of life measured by EQ-5D scale at 90 ± 7 days.

    Time frame: 90 ± 7 days

  7. Modified Rankin Scale (mRS)

    1. Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days. 2. Ordinal distribution of mRS at 90 ± 7 days

    Time frame: 90 ± 7 days

Other outcomes

  1. Symptomatic intracranial hemorrhage (sICH)

    Proportion of subjects with symptomatic intracranial hemorrhage (sICH) within 36 hours (according to the ECASS III criteria for the primary safety analysis, with SITS-MOST and Heidelberg definitions used for supportive analyses).

    Time frame: 36 hours

  2. Death

    Overall mortality rate at 90 days.

    Time frame: 90 days

  3. Systemic bleeding

    Systemic bleeding at 90 days (according to the GUSTO criteria)

    Time frame: 90 days

  4. Adverse events (AEs)/ serious adverse events (SAEs)

    Proportion of patients with adverse events (AEs)/ serious adverse events (SAEs) within 90 ± 7 days.

    Time frame: 90 ± 7 days

  5. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Proportion of subjects experiencing MACCE (defined as ischemic stroke, hemorrhagic stroke, transient ischemic attack, myocardial infarction, or vascular death).

    Time frame: 90 ± 7 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2028, 15 months later.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 15 months is below that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start May 2026 → Nov 2026, primary completion Dec 2027 → Feb 2028 and completion Jun 2028 → Oct 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 20, 2026
StartEst.
Nov 2, 2026was May 2026
Primary completionEst.
Feb 29, 2028was Dec 2027
CompletionEst.
Oct 31, 2028was Jun 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan is now Recruiting
Nov 9, 2026
Start date
May 1, 2026→Nov 2, 2026
Nov 9, 2026
Primary completion
Dec 31, 2027→Feb 29, 2028
Nov 9, 2026
Study completion
Jun 30, 2028→Oct 31, 2028
Nov 9, 2026
Eligibility
1 exclusion criterion removed
What changed in the criteria
Exclusion criteria
  • RemovedSerious neurological deficits before onset (mRS≥2);
Nov 9, 2026
Secondary outcomes
3 time frame changed, 2 added, 3 description edited
What changed in the outcomes
  • AddedNational Institutes of Health Stroke Scale (NIHSS)Time frame: 72 hours and 7 ± 1 days (or at discharge)
  • Time frameModified Rankin Scale (mRS)#290 ± 7 days → 90 days
  • Time frameNational Institutes of Health Stroke Scale (NIHSS)24 hours and 7 days → 72 hours and 7 ± 1 days (or at discharge)
  • DescriptionNational Institutes of Health Stroke Scale (NIHSS): how it is measured was reworded
  • Addedother outcomeMajor Adverse Cardiovascular and Cerebrovascular Events (MACCE)Time frame: 90 ± 7 days
  • Time frameother outcomeAdverse events (AEs)/ serious adverse events (SAEs)90 days → 90 ± 7 days
  • Descriptionother outcomeAdverse events (AEs)/ serious adverse events (SAEs): how it is measured was reworded
  • Descriptionother outcomeSymptomatic intracranial hemorrhage (sICH): how it is measured was reworded
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan is now Recruiting
    Start date May 1, 2026→Nov 2, 2026
    Primary completion Dec 31, 2027→Feb 29, 2028
    Study completion Jun 30, 2028→Oct 31, 2028
    Eligibility 1 exclusion criterion removed
    What changed in the criteria
    Exclusion criteria
    • RemovedSerious neurological deficits before onset (mRS≥2);
    Secondary outcomes 3 time frame changed, 2 added, 3 description edited
    What changed in the outcomes
    • AddedNational Institutes of Health Stroke Scale (NIHSS)Time frame: 72 hours and 7 ± 1 days (or at discharge)
    • Time frameModified Rankin Scale (mRS)#290 ± 7 days → 90 days
    • Time frameNational Institutes of Health Stroke Scale (NIHSS)24 hours and 7 days → 72 hours and 7 ± 1 days (or at discharge)
    • DescriptionNational Institutes of Health Stroke Scale (NIHSS): how it is measured was reworded
    • Addedother outcomeMajor Adverse Cardiovascular and Cerebrovascular Events (MACCE)Time frame: 90 ± 7 days
    • Time frameother outcomeAdverse events (AEs)/ serious adverse events (SAEs)90 days → 90 ± 7 days
    • Descriptionother outcomeAdverse events (AEs)/ serious adverse events (SAEs): how it is measured was reworded
    • Descriptionother outcomeSymptomatic intracranial hemorrhage (sICH): how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07540416
Responsible party
Bo Song (Chief Physician、Professor, The First Affiliated Hospital of Zhengzhou University) — Principal investigator
First posted
Apr 20, 2026
Start date
Nov 2, 2026 (estimated)
Primary completion
Feb 29, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Bo Song, MD
Contact
fccsongb@zzu.edu.cn
+86-371-66278068
Bo Song, MD
study chair · Department of Neurology, the First Affiliated Hospital of Zhengzhou University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion